Literature DB >> 9745058

Laparoscopic or open fundoplication? A complete cost analysis.

A M Blomqvist1, H Lönroth, J Dalenbäck, L Lundell.   

Abstract

BACKGROUND: As part of a prospective observational trial, we set out to determine the direct and indirect costs of an open versus a laparoscopic fundoplication for chronic gastroesophageal reflux disease (GERD).
METHODS: Two groups of patients, each comprising 28 subjects, were studied.
RESULTS: All patients received a functioning fundoplication that did not require any additional therapy. Because 19 and 12 patients in the open and laparoscopy groups, respectively, were employed in the work force, we were able to assess the costs due to loss of production. The mean operating time was similar for both groups, but postoperative stay differed significantly; though it amounted to 8 days for the open group, it was only 2 days for the laparoscopy group. Postoperative sick leave was 29.9 days in the open and 9.9 in the laparoscopy group (p < 0.05). The costs of the operations were 18,363 SEK for laparoscopy and 12,856 SEK for conventional fundoplication. On the other hand, the cost for hospital stay amounted to 35,488 SEK in the open group but was only 25,571 SEK for those undergoing laparoscopy. When we add outpatient visits, endoscopies, and other medical expenses, the total direct costs in the laparoscopy group come to 27,693 SEK, as compared to 37,482 SEK for the open fundoplication. The indirect medical costs, which were dominated by loss of production (36,732 versus 12,126 SEK), came to 37,126 and 12,595 SEK in the open and laparoscopy groups, respectively.
CONCLUSIONS: The total community-based costs for the open and laparoscopic operations for chronic GERD amounted to 74,608 and 40,289 SEK, respectively. Thus, we would recommend the laparoscopic procedure in most cases.

Entities:  

Mesh:

Year:  1998        PMID: 9745058     DOI: 10.1007/s004649900822

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  9 in total

Review 1.  Surgery for hiatal hernia and GERD. Time for reappraisal and a balanced approach ?

Authors:  D E Low
Journal:  Surg Endosc       Date:  2001-06-19       Impact factor: 4.584

Review 2.  Complications of laparoscopic antireflux surgery.

Authors:  D I Watson; A C de Beaux
Journal:  Surg Endosc       Date:  2001-02-06       Impact factor: 4.584

Review 3.  Cost efficacy of laparoscopic vs open surgery. Hospitals vs community.

Authors:  A Cuschieri
Journal:  Surg Endosc       Date:  1998-10       Impact factor: 4.584

4.  The cost of long term therapy for gastro-oesophageal reflux disease: a randomised trial comparing omeprazole and open antireflux surgery.

Authors:  H E Myrvold; L Lundell; P Miettinen; S A Pedersen; B Liedman; J Hatlebakk; R Julkunen; K Levander; M Lamm; C Mattson; J Carlsson; N O Ståhlhammar
Journal:  Gut       Date:  2001-10       Impact factor: 23.059

5.  The cost of gastro-oesophageal reflux disease, dyspepsia and peptic ulcer disease in Sweden.

Authors:  Lars Agréus; Lars Borgquist
Journal:  Pharmacoeconomics       Date:  2002       Impact factor: 4.981

6.  A comparison of pre-operative comorbidities and post-operative outcomes among patients undergoing laparoscopic nissen fundoplication at high- and low-volume centers.

Authors:  Oliver Adrian Varban; Thomas P McCoy; Carl Westcott
Journal:  J Gastrointest Surg       Date:  2011-05-10       Impact factor: 3.452

7.  Open vs laparoscopic partial posterior fundoplication. A prospective randomized trial.

Authors:  B S Håkanson; K B A Thor; A Thorell; O Ljungqvist
Journal:  Surg Endosc       Date:  2006-11-21       Impact factor: 4.584

8.  Tailored antireflux surgery.

Authors:  Z Kala; P Weber; V Prochazka; J Dolina; P Kysela; F Marek
Journal:  J Nutr Health Aging       Date:  2008-11       Impact factor: 4.075

9.  Medical or surgical therapy for erosive reflux esophagitis: cost-utility analysis using a Markov model.

Authors:  Joseph Romagnuolo; Michael A Meier; Daniel C Sadowski
Journal:  Ann Surg       Date:  2002-08       Impact factor: 12.969

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.